Thursday, 15 October 2026European Markets

FIN.ETANG BERRE Stock Bullish Momentum With A 25% Jump In The Last 10 Sessions

Loading stream...

(vianews) - shares of fin.etang berre (cac 40: berr.pa) jumped by a staggering 25.56% in 10 sessions from €9 to €11.30 at 20:52 est on thursday, following the last session's downward trend. cac 40 is jumping 0.36% to €7,312.73, after three successive sessions in a row of gains.

about fin.etang berre

financiere et immobiliere de l'etang de berre et de la mediterranee société anonyme engages in the caravanning, and parking and restaurant rental businesses. financiere et immobiliere de l'etang de berre et de la mediterranee société was incorporated in 1971 and is headquartered in carry-le-rouet, france.

earnings per share

as for profitability, fin.etang berre has a trailing twelve months eps of €0.04.

pe ratio

fin.etang berre has a trailing twelve months price to earnings ratio of 282.5. meaning, the purchaser of the share is investing €282.5 for every euro of annual earnings.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, fin.etang berre's stock is considered to be oversold (<=20).

volatility

fin.etang berre's last week, last month's, and last quarter's current intraday variation average was 8.52%, 8.52%, and 9.11%.

fin.etang berre's highest amplitude of average volatility was 9.11% (last week), 9.11% (last month), and 9.11% (last quarter).

volume

today's last reported volume for fin.etang berre is 1349 which is 1233.33% above its average volume of 75.

more news about fin.etang berre (berr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com